Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Amphastar Pharmaceuticals, Inc. Form 4 May 22, 2015 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading PRINS RICHARD K Issuer Symbol Amphastar Pharmaceuticals, Inc. (Check all applicable) [AMPH] (Last) (First) (Middle) 3. Date of Earliest Transaction X_ Director 10% Owner Officer (give title Other (specify (Month/Day/Year) below) below) C/O AMPHASTAR 05/20/2015 PHARMACEUTICALS, INC., 11570 6TH STREET (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting RANCHO Person CUCAMONGA, CA 91730 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 4. Securities Acquired (A) 5. Amount of 7. Nature of 2. Transaction Date 2A. Deemed 3. 6. Security (Month/Day/Year) Transaction Disposed of (D) Securities Ownership Indirect Execution Date, if (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial any (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (\mathbf{I}) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price Common 05/20/2015 \$11.68 D Μ 13,945 Α 49,996 Stock \$ Common 05/20/2015 S 13,945 D 14.7904 36,051 D Stock (1)Common 05/21/2015 Μ 11.901 \$ 11.68 47,952 D A Stock Common 05/21/2015 Μ 1.664 D D \$ 10.77 49,616 Stock

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Common Stock	05/21/2015	S	13,565	D	\$ 14.757 (2)	36,051	D
Common Stock	05/22/2015	М	1,942	А	\$ 10.77	37,993	D
Common Stock	05/22/2015	S	1,942	D	\$ 14.755 (3)	36,051	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 11.68	05/20/2015		М		13,945	(4)	12/18/2015	Common Stock	13,945
Stock Option (right to buy)	\$ 11.68	05/21/2015		М		11,901	(4)	12/18/2015	Common Stock	11,901
Stock Option (right to buy)	\$ 10.77	05/21/2015		М		1,664	<u>(4)</u>	12/15/2017	Common Stock	1,664
Stock Option (right to buy)	\$ 10.77	05/22/2015		М		1,942	<u>(4)</u>	12/15/2017	Common Stock	1,942

Reporting Owners

Reporting Owner Name / Address

Relationships

8 E S () X

Director 10% Owner Officer Other

PRINS RICHARD K C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730

Signatures

/s/ Ken Stupak, by power of 05/22/2015 attorney

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$14.76 to \$14.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the

- (1) to \$14.91, inclusive. The Reporting Ferson undertakes to provide to the issuer, any security holder of the issuer, of the start of the start of the start of the ranges and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$14.70 to \$15.00, inclusive.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$14.70 to \$14.80, inclusive.
- (4) Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.